论文部分内容阅读
作者于1987年在国内率先研制丝裂霉素微胶囊(MMC·mc)肾动脉栓塞试验材料,1988年进行了狗的动物试验和临床应用。 作为治疗肾癌的丝裂霉素微胶囊,采取了二种成囊方式,乙基纤维囊壁的微胶囊及聚脲囊壁的微胶囊。以狗作为试验动物,从狗肾动脉注射入栓塞材料:MMC·mc 8—10mg(0.7—1.3mg/kg),1×1mm~2明胶海绵以及30ml生理盐水的混合液。对照组动物实验的栓塞物质采用丝裂霉素代替丝裂霉素微胶囊。不同时间血清中丝裂霉素的浓度应用抑菌管碟法进行测定。实验动物分别在不同时间杀死,取出已栓塞的肾脏,经组织匀浆后,测定其MMC浓度。
The authors took the lead in the development of mitomycin microcapsule (MMC·mc) renal artery embolization test materials in China in 1987 and carried out dog animal experiments and clinical applications in 1988. As a mitomycin microcapsule for the treatment of kidney cancer, two methods of encapsulation were used, microcapsules of an ethylcellulose capsule wall and microcapsules of a polyurea capsule wall. Using a dog as a test animal, a mixture of embolic material: MMC·mc 8-10 mg (0.7-1.3 mg/kg), 1×1 mm-2 gelatin sponge, and 30 ml of normal saline was injected from the renal artery of the dog. Mitochondrion was used instead of mitomycin microcapsules in the embolized material of the control animals. The concentration of mitomycin in the serum at different times was measured using the antibacterial dish method. The experimental animals were killed at different times, the embolized kidneys were removed, and the MMC concentrations were determined after homogenization.